{
  "turn_global_index": 236,
  "session_index": 22,
  "session_id": "ultrachat_251049",
  "turn_in_session": 3,
  "date": "2023/05/29 (Mon) 05:39",
  "role": "assistant",
  "content": "Xintela is a biotech company that focuses on the development of stem cell therapies for various medical conditions. The research that led to the founding of Xintela was conducted by a group of scientists at Lund University in Sweden, led by Professor Anders Hjerpe.\n\nThe research focused on the properties of a particular protein called integrins, which are involved in cell adhesion and play a crucial role in stem cell biology. Integrins are important for stem cell differentiation, self-renewal, and migration, but their role in tissue regeneration is not well understood.\n\nThe researchers at Lund University discovered that certain integrin combinations were critical for the self-renewal and differentiation of stem cells, and that manipulating these integrins could control the behavior of stem cells.\n\nBased on these findings, the researchers founded Xintela in 2009 to develop new stem cell therapies for various medical conditions, including cancer, wound healing, and neurodegenerative diseases such as Alzheimer's and Parkinson's.\n\nXintela's stem cell technology platform is based on manipulating integrins in various ways to enhance the therapeutic properties of stem cells. The company is currently conducting clinical trials for its stem cell therapy for knee osteoarthritis, and is also developing therapies for other medical conditions.",
  "has_answer": false
}